147 CLINICAL CONSEQUENCES OF OFF-LABEL REDUCED DOSING OF NOACS IN AF FUNDING This study did not receive funding. GJG is supported by a VENI and VIDI grant from the Netherlands Organisation for Health Research and Development (ZonMw numbers 016.166.030 and 016.196.304). POTENTIAL CONFLICTS OF INTEREST FR, MH and GJG report unrestricted institutional grants for performing research in the field of atrial fibrillation from Boehringer Ingelheim, Bayer Healthcare, BristolMyers Squibb/Pfizer Alliance and Daiichi Sankyo. CG reports personal fees from AbbVie, Abiomed, Anthos Therapeutics Bayer Healthcare, Boston Scientific, CeleCor, Correvio, Espero, Medscape, Medtronic, Merck, Novo Nordisk, Philips, Roche, Rho Pharmaceuticals and the National Institutes of Health; grants and personal fees from Boehringer-Ingelheim, BMS Pfizer and Janssen, Novartis and The Medicines Company; grants from Akros, Apple, AstraZeneca, Daiichi-Sankyo, Glaxo Smith Kline, Medtronic Foundation and the US Food and Drug Administration. SvD reports an unrestricted research grant from Stoffels Hornstra. The other authors declare that they have no conflicts of interest. CONTRIBUTORS LJ, RvM, CvdD, GJG and SvD conceived and initiated the study. LJ, RvM, CvdD and SvD screened and selected the articles for inclusion. LJ, RvM and SvD performed the data extraction and risk of bias assessment. LJ, RvM and SvD prepared the dataset. SvD performed the statistical analyses. All authors interpreted the results. LJ, RvM and SvD wrote the first version of the manuscript. All authors critically reviewed and revised the manuscript. 8
RkJQdWJsaXNoZXIy MTk4NDMw